Very late delayed-allergic reaction to natalizumab not associated with neutralizing antibodies

Multiple Sclerosis

Volumn 15, Issue 4, 2009, Pages 525-526

  Killestein, J ^a   Jasperse, B ^a   Liedorp, M ^a   Seewann, A ^a   Polman, C H ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON BETA SERINE; NATALIZUMAB; NEUTRALIZING ANTIBODY; STEROID;

ADULT; ANAMNESIS; ARTHRALGIA; ARTICLE; CASE REPORT; DELAYED HYPERSENSITIVITY; DISEASE DURATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG REEXPOSURE; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; HUMAN TISSUE; MALE; MULTIPLE SCLEROSIS; SEROLOGY; SERUM SICKNESS; SKIN BIOPSY; SYNOVIAL FLUID;

ANTIBODIES; ANTIBODIES, MONOCLONAL; HUMANS; HYPERSENSITIVITY, DELAYED; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; SERUM SICKNESS;

EID: 63449117107     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458508101322     Document Type: Article

References (8)

1. Hellwig, K, Schimrigk, S, Fischer, M, et al. Allergic and nonallergic delayed infusion reactions during natalizumab therapy. Arch Neurol 2008; 65: 656-658.
2. Krumbholz, M, Pellkofer, H, Gold, R, Hoffmann, LA, Hohlfeld, R, Kumpfel, T. Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies. Arch Neurol 2007; 64: 1331-1333.
3. Leussink, VI, Lehmann, HC, Hartung, HP, Gold, R, Kieseier, BC. Type III systemic allergic reaction to natalizumab. Arch Neurol 2008; 65: 851-852.
4. Miller, DH, Khan, OA, Sheremata, WA, et al. International Natalizumab Multiple Sclerosis Trial Group. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348: 15-23.
5. Phillips, JT, OConnor, PW, Havrdova, E, et al. Infusionrelated hypersensitivity reactions during natalizumab treatment. Neurology 2006; 67: 1717-1718.
6. Polman, CH, OConnor, PW, Havrdova, E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910.
7. Rudick, RA, Stuart, WH, Calabresi, PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354: 911-923.
8. Calabresi, PA, Giovannoni, G, Confavreux, C, et al. MPH For the AFFIRM and SENTINEL Investigators. The incidence and significance of anti-natalizumab antibodies: Results from AFFIRM and SENTINEL. Neurology 2007; 69: 1391-1403.